SCHEMBL4015933

SCHEMBL4015933

CN(C)c1cccc(-c2ccc3nonc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.46
LRRK2 Q5S007 1/20 0.45
TDO2 P48775 1/20 0.43
FYN P06241 3/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
GFER P55789 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
TSHR P16473 1/20 0.39
ENPP2 Q13822 1/20 0.39
AURKA O14965 1/20 0.38
PSMB5 P28074 2/20 0.38
IP6K1 Q92551 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4499060 0.84 CYP1A2 (0.49) LRRK2TDO2ALDH1A1KDM4ENPC1
SCHEMBL19698858 0.78 ALDH1A1 (0.54) NOTUMLRRK2FYNALDH1A1KDM4E
SCHEMBL30602821 0.78 ALDH1A1 (0.58) NOTUMLRRK2FYNALDH1A1KDM4E
SCHEMBL3078778 0.78 ENPP2 (0.58) TDO2ALDH1A1KDM4EHSD17B10TSHR
SCHEMBL4014407 0.76 ENPP2 (0.43) TDO2ALDH1A1KDM4ENPC1TP53
SCHEMBL29520575 0.74 PNPLA2 (0.53) NOTUMFYNALDH1A1KDM4ENPC1
SCHEMBL4022329 0.74 ENPP2 (0.62) ENPP2
SCHEMBL980630 0.74 MAP4K4 (0.50) TDO2ALDH1A1KDM4ENPC1TP53
SCHEMBL4016472 0.73 TDO2 (0.40) TDO2NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL4013687 0.73 LCK (0.42) TDO2FYNALDH1A1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632851-B2 Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers NOVARTIS AG (CH) 2009-12-15 US disclosed
EP-1613610-B1 BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS NOVARTIS AG (CH) 2009-07-01 EP disclosed
US-20060093551-A1 Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers NOVARTIS AG (CH) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060093551-A1 Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers H1-3, MKI67, H1-5 NOTUM 3595/4885LRRK2 4393/4885TDO2 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.